Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

Expert Opinion on Drug Safety, Journal Year: 2023, Volume and Issue: 22(5), P. 355 - 362

Published: May 4, 2023

Biological treatments deeply changed the management of moderate-to-severe forms psoriasis. Among available biological therapies, interleukin (IL)-17 inhibitors, secukinumab, ixekizumab, brodalumab, and bimekizumab represent one most rapid effective biologic classes for Bimekizumab, latest IL-17 inhibitor, is a humanized monoclonal immunoglobulin (Ig)G1 antibody that acts by neutralizing both IL-17A IL-17F, showing unique mechanism action differing from ixekizumab secukinumab (selective IL17A inhibitor), as well brodalumab (antagonist IL17 receptor).This review aims to evaluate safety profile in treatment plaque psoriasis.The efficacy have been reported several phase II III clinical trials, even longer-term period. Moreover, trials also showed significantly higher compared other classes, including anti-TNF, anti-IL-12/23, another secukinumab. Although numerous biologics are currently psoriasis, some patients may result resistant and/or experience psoriatic flares during or after withdrawal. In this scenario, an additional valuable alternative with

Language: Английский

---

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2024, Volume and Issue: Volume 17, P. 829 - 842

Published: April 1, 2024

Psoriasis pathogenesis is influenced by genetic factors and characterized a complex interplay between predisposition various environmental triggers. These triggers set off metabolic processes involving inflammation, cell signaling, immune response dysregulation, antigen presentation. Several types of innate adaptive cells are involved in psoriasis. Among the cytokine cascade which leads to psoriasis development, interleukin (IL)-23/Th17 axis, especially IL-17 production, emerges as crucial. Recognizing pivotal role this axis has facilitated development selective effective biological drugs, such anti-IL17 anti-IL23 monoclonal antibodies. drugs aim achieve complete or near-complete disappearance psoriatic lesions, indicated PASI100 PASI90 responses, respectively. In context, our review was delve into functioning IL-23/Th17 its dysregulation pathogenesis, therapeutic potential inhibition. Currently, 4 (secukinumab, ixekizumab, bimekizumab brodalumab) 3 (guselkumab, risankizumab tildrakizumab) have been approved. All these showed high levels effectiveness both clinical trials real-life experiences, with an excellent profile terms safety. Certainly, furthers studies will allow for better characterization biologics' profile, order administer right drug patients at moment.

Language: Английский

---

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2023, Volume and Issue: Volume 16, P. 1677 - 1690

Published: June 1, 2023

Abstract: Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being potentially life-threatening condition, characterized by recurring episodes or flares widespread cutaneous erythema with macroscopic sterile pustules. An irregular innate immune response linked to GPP, which considered an auto-inflammatory disorder, while adaptive immunopathogenic responses are involved in pathogenesis. In consequence, different cytokine cascades have been suggested be mainly the pathogenesis each form, interleukin (IL)23/IL17 axis implied plaque IL36 pathway GPP. As regards GPP treatment, conventional systemic drugs available for usually used as first-line treatment option. However, contraindications adverse events often limit use these therapies. this scenario, biologic may represent promising To date, even if 12 biologics approved none where they employed off-label. Recently, spesolimab, anti-IL36 receptor monoclonal antibody, has recently The purpose article assess current literature about biological therapies establish basis shared management algorithm. Keywords:

Language: Английский

---

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2023, Volume and Issue: Volume 16, P. 2045 - 2059

Published: Aug. 1, 2023

Abstract: Erythrodermic psoriasis (EP) is a severe and rare variant of (less than 3% cases), characterized by generalized scaling erythema affecting more 90% body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fatigue, dehydration, serum electrolyte disturbances, tachycardia making this condition possible life-threatening disease, particularly if appropriate treatments are not performed. In scenario, effective safe therapies required. Unfortunately, the rarity makes head-to-head Phase III trials challenging, leading to lack established guidelines for its management. Globally, conventional drugs cyclosporine, methotrexate, retinoids often have contraindications linked patients' comorbidities shown high profile efficacy safety. Recently, development biologic including anti-tumor necrosis factor-α anti-interleukin 12– 23, 17 has revealed favorable results management plaque psoriasis, them also therapeutic option disease. However, their use still off-label. The aim our study was review current literature on treatment EPs order offer wide perspective application Keywords: erythrodermic treatment,

Language: Английский

---

Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains—Should Psychosocial Life Impairment Be Considered a Comorbidity?

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(1), P. 223 - 223

Published: Jan. 2, 2025

Background/Objectives: Psoriasis is a chronic inflammatory skin disease that may have significant impact on patients’ quality of life. Alongside clinical scores, treatment goals include improvements in life, divided into its social, working and psychosocial life aspects. Indeed, psychological impairment should always be considered the management moderate-to-severe psoriasis. Tildrakizumab, an anti-IL-23, approved for Both trials real-life studies show efficacy safety; however, no evaluated how tildrakizumab improve different domains including physical, psychological, social aspects The objective was to evaluate effectiveness psoriasis, focusing all Methods: A 28-week multicenter, real-life, retrospective study performed enrolling patients affected by psoriasis undergoing with tildrakizumab. PASI DLQI were at each follow-up (W16, W28). sub-analysis question quality-of-life. Results: total 62 enrolled. At week 28, 97.1%, 85.7%, 54.3% achieved PASI75, PASI90, PASI100, respectively. showed reduction from baseline (20.3 ± 5.5) 28 (0.9 2.2, p < 0.0001), up 82.9% achieving 1. Sub-analysis (Q1–Q10) value answer 28. Conclusions: results confirm as effective safe real positively affecting already appreciable 16 follow-up.

Language: Английский

---

Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study

Dermatology and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Language: Английский

---

Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2023, Volume and Issue: 37(12), P. 2517 - 2525

Published: Aug. 26, 2023

Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It approved for treatment moderate-to-severe plaque psoriasis. Real-world evidence on effectiveness and safety tildrakizumab limited.To assess at 24 weeks in patients psoriasis routine clinical practice.Retrospective, observational, multicentre study including adult treated under real-life conditions. Patient data were extracted from anonymized electronic medical records. Statistical analysis was performed using SPSS22.A total 190 included. About 53.9% men mean age 51.45 (SD 3.9) BMI 29.13 6.21). 79.8% (132 out 190) had previously received biological therapy (BT) 17.3% (33 191) psoriatic arthritis. Baseline PASI 10.7 6.53). Up to 109 reached Week this point baseline decreased 1.7 4.8), representing an 88.79% reduction. At 6 months, 87.1% 40.3% achieved ≤3 ≤1, respectively. BSA 13.2 10.07) 1.6 4.40) DLQI went 12.5 7.12) 1.2 3.27). Multivariate showed no differences when correlated gender, obesity, arthritis or prior exposure BT. The rate adverse events (AE) 5.9% (11 190), where infections most frequent AE (4 11). One patient suffered haemorrhagic ictus one died due causes unrelated study.Tildrakizumab effective safe large cohort setting.

Language: Английский

---

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2024, Volume and Issue: Volume 17, P. 1037 - 1042

Published: May 1, 2024

Abstract: Tildrakizumab is a humanised IgG1/k-type monoclonal antibody that targets the p19 protein subunit of IL23. Despite its effectiveness and safety have been widely reported by clinical trials real-life experiences, data regarding use on patients who previously failed anti-IL17 (brodalumab, ixekizumab, bimekizumab and/or secukinumab) are scant. Therefore, further studies this topic would be beneficial for clinicians in guiding selection biologic shifting, considering anti-IL23, − 12/23, -IL17 partially share their therapeutic targets. In context, we performed 28-week, single-center, real-life, retrospective study, with aim assessing efficacy tildrakizumab anti-IL17, also focusing attention psoriasis located difficult-to-treat areas (scalp, palms or soles, fingernails, genitals). A total 23 (12 male, 52.2%; mean age 52.8 ± 12.4 years) were enrolled. Of these, 11 (47.8%) secukinumab, 7 (30.4%) 3 (13.0%) brodalumab, 1 (4.3%) both secukinumab ixekizumab bimekizumab. At baseline, PASI BSA 12.8 5.9 18.7 9.6, respectively. W16 PASI75 PASI90 response achieved 15 (65.2%), 9 (39.1%) patients, respectively, whereas 19 (82.6%) 13 (56.6%) subjects reached these scores at W28. One case primary inefficacy secondary assessed. Finally, no severe adverse events collected. seems to valuable option selected unresponsive suggesting prior exposure biological therapies seem not directly affect effectiveness. Keywords: Tildrakizumab, psoriasis, anti-IL23

Language: Английский

---

Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation

Expert Opinion on Drug Safety, Journal Year: 2023, Volume and Issue: 22(11), P. 1003 - 1010

Published: Sept. 28, 2023

Generalized pustular psoriasis (GPP) is a rare form of (less 1% cases). Currently, GPP recognized as clinical entity, distinguished from plaque psoriasis. However, there are not guidelines for management and treatments often derived Therefore, conventional systemic drugs usually used first-line treatment options, biologics still off label. Recently, spesolimab, an anti-IL36 receptor humanized IgG1 monoclonal antibody, has been specifically approved disease, revolutionizing scenario.The aim this review to investigate current literature on the use spesolimab underline its potential role in offer perspective. Literature research using Google Scholar, Pubmed, Embase, Cochrane Skin, clinicaltrials.gov databases was performed, selecting most relevant manuscripts.Spesolimab efficacious consistent favorable safety profile patients presenting with flare. despite excellent results terms efficacy have reported by both trials very limited real-life experiences, long-term data, especially flare-up prevention, scant. Thus, while available data encouraging, further warranted understand efficacy, safety, outcomes associated GPP.

Language: Английский

---

The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study

Journal of Dermatological Treatment, Journal Year: 2023, Volume and Issue: 35(1)

Published: Dec. 18, 2023

Language: Английский

---